The new 27,000 square foot facility, located next to the company’s research and development labs, has clinical and commercial manufacturing scale capabilities designed to support its growing pipeline of targeted alpha therapies.
Part of a 15 year lease agreement with McMaster, the facility is expected to produce more than 100,000 doses of TATs per year, at full capacity.
Fusion’s cancer therapies contain alpha-emitting isotopes that target and eradicate tumor cells with microscopic precision.
Expected to be fully operational by 2024, the facility will support the research, development and production of next-generation radiopharmaceuticals for the treatment of various cancers.
“Manufacturing and supply chain are critical components of radiopharmaceutical development and commercialization,” said John Valliant, chief executive officer at Fusion.
“Having spun out of a radiopharmaceutical manufacturer, this is a core competency for Fusion, and we believe we are well-positioned to scale production in support of our pipeline of TATs, which now includes five clinical-stage programs,” he added.
“The location of the facility, adjacent to both our internal research organization and McMaster University, a world-class institution that specializes in medical isotope research and training, enables us to efficiently advance new TATs and hire experienced talent to execute on our clinical and future commercial plans.”
Fusion plans to continue to leverage existing contract development and manufacturing organization (CDMO) relationships with Cardinal Health, SpectronRx, Radiomedix and AtomVie, in an effort to ensure scalability and redundancy.
